glp 1 cause anxiety does help with depression What do the studies actually show about GLP-1s and Beyond the scale: How GLP-1

A recent Phase 2 randomised placebo-controlled trial tested efinopegdutide in people with obesity over a 26-week period, where participants were randomly assigned weekly treatment with either placebo, 5 mg, 7.4 mg, 10 mg efinopegdutide, or 3 mg liraglutide daily

Many practitioners prefer the no-DAC version specifically because it produces sharp GH pulses that more closely mimic natural physiology

And when Novo Nordisk faced production issues, the decision to choose Eli Lilly's Mounjaro and Zepbound over Novo Nordisk's Wagovy became even easier

What are the options

Based on current evidence, oral supplements have a stronger scientific foundation

Meanwhile, another study in The New England Journal of Medicine shows just 33% of the dose of one popular GLP-1 drove 72% of the weight loss at week 72 with a lower side effect profile